Pro-inflammatory cytokines and associated inflammatory signaling

Pro-inflammatory cytokines and associated inflammatory signaling refers to a complex network of secreted proteins and intracellular pathways that orchestrate the host's response to infection and injury. Key cytokines in this group include Tumor Necrosis Factor-alpha (TNF-alpha), Interleukin-1 (IL-1), and Interleukin-6 (IL-6), which are primarily produced by activated macrophages and lymphocytes (StatPearls, 2023). These molecules bind to specific receptors on target cells, initiating downstream signaling cascades such as the NF-kappaB, MAPK, and JAK-STAT pathways to promote the expression of inflammatory genes (Nature Reviews Immunology, 2018). While essential for acute defense, chronic or excessive activation of these pathways is a primary driver of autoimmune diseases, such as rheumatoid arthritis and psoriasis, as well as systemic conditions like sepsis (Frontiers in Immunology, 2021). Pharmacological intervention focuses on inhibiting specific nodes within this network to dampen pathological inflammation while attempting to preserve baseline immune function. Common therapeutic strategies include the use of monoclonal antibodies to neutralize circulating cytokines or small molecule inhibitors to target intracellular kinases (PubMed, 2022).

Other names

Pro-inflammatory mediatorsInflammatory cytokine signalingCytokine networkPro-inflammatory signaling pathways

Therapeutic agents modulate this system by neutralizing pro-inflammatory ligands, blocking cognate receptor binding, or inhibiting intracellular signaling transducers like Janus kinases (JAKs) to suppress the transcription of inflammatory genes (PubMed, 2020).